menu search

CYDY / CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A

CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A
VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, Nitya Ray, Ph.D., Chief Operating Officer and Chief Technology Officer and Christopher Recknor, M.D., Senior Executive VP of Clinical Operations of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 30 minutes and 90 minutes will be dedicated to live questions and answers. Read More
Posted: Oct 7 2021, 14:27
Author Name: GlobeNewsWire
Views: 111798

CYDY News  

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

By GlobeNewsWire
December 23, 2022

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing l more_horizontal

CytoDyn touts publication of paper on suppression of human and simian immunodeficiency virus replication with leronlimab

By Proactive Investors
April 12, 2022

CytoDyn touts publication of paper on suppression of human and simian immunodeficiency virus replication with leronlimab

CytoDyn Inc, a late-stage biotechnology company developing its flagship drug leronlimab for multiple indications, has revealed the publication of a p more_horizontal

CytoDyn: Holding Onto The Ruins From An End Of An Era

By Seeking Alpha
March 30, 2022

CytoDyn: Holding Onto The Ruins From An End Of An Era

CytoDyn: Holding Onto The Ruins From An End Of An Era more_horizontal

CytoDyn to Hold Webcast to Provide Company Update

By GlobeNewsWire
March 30, 2022

CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology compan more_horizontal

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

By Market Watch
February 22, 2022

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the more_horizontal

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

By Market Watch
February 22, 2022

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the more_horizontal

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

By Market Watch
February 22, 2022

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the more_horizontal


Search within

Pages Search Results: